Cell No. : Cell Name
RCB5673 : Y-MESO-28
update : 2024/03/13
|
| Comment | |
| Comment from the depositor | Human malignant pleural mesothelioma cell line. This cell line was established from the pleural effusion of epithelioid type MPM of a patient. |
| Terms and conditions | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Cancer Res 2011 71(3):873-83) designated by the DEPOSITOR is requested.
|
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
SEKIDO, Yoshitaka
|
| Originator |
SEKIDO, Yoshitaka
|
| Year of deposit |
2022
|
| Cloning (depositor) |
Yes
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
65 years
|
| Tissue |
pleural effusion
|
| Primary focus |
malignant pleural mesothelioma
|
| Disease name |
malignant pleural mesothelioma
|
| Tumor |
epithelioid type MPM
|
| Classification |
cancer
|
| Recombinant |
non-recombinant
|
| Year of origin |
2007
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_5185
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Adherent cells
|
Adherent cells
|
| Culture medium |
RPMI1640 + 10% FBS
|
RPMI1640 + 10% FBS
|
| Antibiotics |
1% antimicrobial
|
Free
|
|
Passage method |
0.25w/v% Trypsin + 1mmol/l EDTA（FUJIFILM 209-16941）
|
0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
|
Culture information
|
Passage ratio |
1 : 5-8 split
|
1 : 3 split
|
| SC frequency |
Subculture : 1-2 times/week
|
Subculture : 1-2 times/week
|
| Temperature |
37
℃
|
37
℃
|
| CO2 concentration |
5
%
|
5
%
|
| Freeze medium |
CELLBANKER
|
CELLBANKER 1
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
(-)
|
(-)
|
| Animal PCR |
|
OK
|
| STR(human) |
|
OK
|
|
deposit info
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
11,12
|
8
|
11
|
9
|
14,16
|
9
|
X,Y
|
10
|
10,12
|
|
|
lot info
|
|
| Reference information |
Reference |
11
|
| User's Publication |
0
|
| Reference |
|
16476
Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, Tsuji Y, Hamaguchi K, Yasunaga M, Nishiya Y, Suzuki M, Saito JI, Yatsunami R, Nakamura S, Sekido Y, Mori K.
The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma
Am J Cancer Res
2020
;10(12):4399-4415
PubMed ID: 33415007
|
|
16027
Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.
TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation
Oncogene
2018
38(11):1966-1978
PubMed ID: 30401981
DOI: 10.1038/s41388-018-0417-7
|
|
16467
Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.
Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis
Cancer Lett
2017
385:215-224.
PubMed ID: 27773750
DOI: 10.1016/j.canlet.2016.10.020
|
|
16477
Kato T, Sato T, Yokoi K, Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells
Oncogene
2017
36(39):5522-5531
PubMed ID: 28553954
DOI: 10.1038/onc.2017.147
|
|
16468
Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells
Cancer Sci
2015
106(8):990-9.
PubMed ID: 26011428
DOI: 10.1111/cas.12698
|
|
16469
Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.
LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade
Oncogene
2015
34(1):73-83
PubMed ID: 24336325
DOI: 10.1038/onc.2013.528
|
|
16471
Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y.
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes
Oncogene
2012
31(49):5117-22
PubMed ID: 22286761
DOI: 10.1038/onc.2012.5
|
|
16472
Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Yokoi K, Osada H, Sekido Y.
Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma
J Thorac Oncol
2012
7(5):890-9
PubMed ID: 22722789
DOI: 10.1097/JTO.0b013e31824af2db
|
|
16474
Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma
Cancer Res
2011
71(3):873-83
PubMed ID: 21245096
DOI: 10.1158/0008-5472.CAN-10-2164
|
|
16457
Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells
Mol Med Rep
2009
2(2):181-8
PubMed ID: 21475810
DOI: 10.3892/mmr_00000081
|
|
16475
Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y.
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
Carcinogenesis
2009
30(7):1097-105
PubMed ID: 19380521
DOI: 10.1093/carcin/bgp097
|
Back
Top
CELL BANK Website